PL370453A1 - Thymosin augmentation of genetic immunization - Google Patents

Thymosin augmentation of genetic immunization

Info

Publication number: PL370453A1
Authority: PL; Poland
Prior art keywords: hepatitis; virus; thymosin; augmentation; genetic immunization
Prior art date: 2001-10-26

Application number

PL02370453A

Other languages

English (en)

Polish (pl)

Inventor

Jack R. Wands

Original Assignee

Rhode Island Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-26

Filing date

2002-10-28

Publication date

2005-05-30

2002-10-28 Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital

2005-05-30 Publication of PL370453A1 publication Critical patent/PL370453A1/xx

Links

102000007501 Thymosin Human genes 0.000 title abstract 4
108010046075 Thymosin Proteins 0.000 title abstract 4
230000003053 immunization Effects 0.000 title abstract 3
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title abstract 2
230000003416 augmentation Effects 0.000 title 1
230000002068 genetic effect Effects 0.000 title 1
238000002649 immunization Methods 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 4
102000040430 polynucleotide Human genes 0.000 abstract 2
108091033319 polynucleotide Proteins 0.000 abstract 2
239000002157 polynucleotide Substances 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
230000024932 T cell mediated immunity Effects 0.000 abstract 1
208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Zoology (AREA)
Oncology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

PL02370453A 2001-10-26 2002-10-28 Thymosin augmentation of genetic immunization PL370453A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US33063801P	2001-10-26	2001-10-26

Publications (1)

Publication Number	Publication Date
PL370453A1 true PL370453A1 (en)	2005-05-30

Family

ID=23290629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02370453A PL370453A1 (en)	2001-10-26	2002-10-28	Thymosin augmentation of genetic immunization

Country Status (21)

Country	Link
US (1)	US20050054845A1 (de)
EP (1)	EP1448223B1 (de)
JP (1)	JP2005506997A (de)
KR (1)	KR100902197B1 (de)
CN (1)	CN1269524C (de)
AT (1)	ATE382365T1 (de)
BR (1)	BR0213554A (de)
CA (1)	CA2464795A1 (de)
CY (1)	CY1107371T1 (de)
DE (1)	DE60224435T2 (de)
DK (1)	DK1448223T3 (de)
EA (1)	EA006743B1 (de)
ES (1)	ES2299626T3 (de)
IL (1)	IL161603A0 (de)
MX (1)	MXPA04003867A (de)
NO (1)	NO20042124L (de)
NZ (1)	NZ532863A (de)
PL (1)	PL370453A1 (de)
PT (1)	PT1448223E (de)
UA (1)	UA81613C2 (de)
WO (1)	WO2003035010A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA90493C2 (ru) *	2004-12-06	2010-05-11	Сайклон Фармасютикалс, Инк	Альфа-тимозиновые пептиды как адьюванты противораковых вакцин
CN102458470B (zh)	2009-05-08	2016-01-20	赛生制药有限公司	作为疫苗增强剂的α胸腺素肽

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4079127A (en) *	1976-10-28	1978-03-14	Board Of Regents Of The University Of Texas	Thymosin alpha 1
US4116951A (en) *	1977-04-22	1978-09-26	Hoffmann-La Roche Inc.	[Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) *	1978-01-23	1979-04-10	Hoffmann-La Roche Inc.	Synthesis of thymosin α1
DE2919592A1 (de) *	1979-05-15	1981-01-15	Max Planck Gesellschaft	Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
TW224053B (de) *	1991-09-13	1994-05-21	Paul B Chretien
US5620896A (en) *	1992-03-23	1997-04-15	University Of Massachusetts Medical Center	DNA vaccines against rotavirus infections
US5593972A (en) *	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
US6288033B1 (en) *	1998-09-25	2001-09-11	Sciclone Pharmaceuticals, Inc.	Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir

2002
- 2002-10-28 DE DE60224435T patent/DE60224435T2/de not_active Expired - Lifetime
- 2002-10-28 IL IL16160302A patent/IL161603A0/xx unknown
- 2002-10-28 NZ NZ532863A patent/NZ532863A/en unknown
- 2002-10-28 UA UA20040503963A patent/UA81613C2/ru unknown
- 2002-10-28 CN CNB028212770A patent/CN1269524C/zh not_active Expired - Fee Related
- 2002-10-28 CA CA002464795A patent/CA2464795A1/en not_active Abandoned
- 2002-10-28 WO PCT/US2002/034535 patent/WO2003035010A2/en not_active Ceased
- 2002-10-28 PT PT02795564T patent/PT1448223E/pt unknown
- 2002-10-28 MX MXPA04003867A patent/MXPA04003867A/es active IP Right Grant
- 2002-10-28 US US10/493,411 patent/US20050054845A1/en not_active Abandoned
- 2002-10-28 BR BR0213554-0A patent/BR0213554A/pt not_active IP Right Cessation
- 2002-10-28 KR KR1020047006231A patent/KR100902197B1/ko not_active Expired - Fee Related
- 2002-10-28 PL PL02370453A patent/PL370453A1/xx unknown
- 2002-10-28 JP JP2003537579A patent/JP2005506997A/ja active Pending
- 2002-10-28 EP EP02795564A patent/EP1448223B1/de not_active Expired - Lifetime
- 2002-10-28 DK DK02795564T patent/DK1448223T3/da active
- 2002-10-28 AT AT02795564T patent/ATE382365T1/de not_active IP Right Cessation
- 2002-10-28 ES ES02795564T patent/ES2299626T3/es not_active Expired - Lifetime
- 2002-10-28 EA EA200400534A patent/EA006743B1/ru not_active IP Right Cessation
2004
- 2004-05-24 NO NO20042124A patent/NO20042124L/no not_active Application Discontinuation
2008
- 2008-03-28 CY CY20081100354T patent/CY1107371T1/el unknown

Also Published As

Publication number	Publication date
IL161603A0 (en)	2004-09-27
PT1448223E (pt)	2008-01-23
KR20040089075A (ko)	2004-10-20
MXPA04003867A (es)	2005-06-17
CN1604789A (zh)	2005-04-06
CA2464795A1 (en)	2003-05-01
BR0213554A (pt)	2004-10-26
NZ532863A (en)	2006-07-28
EA200400534A1 (ru)	2004-12-30
ES2299626T3 (es)	2008-06-01
EA006743B1 (ru)	2006-04-28
CN1269524C (zh)	2006-08-16
ATE382365T1 (de)	2008-01-15
NO20042124L (no)	2004-05-24
DK1448223T3 (da)	2008-02-18
DE60224435T2 (de)	2009-01-02
KR100902197B1 (ko)	2009-06-11
WO2003035010A3 (en)	2003-12-04
JP2005506997A (ja)	2005-03-10
DE60224435D1 (de)	2008-02-14
EP1448223A4 (de)	2005-11-16
WO2003035010A2 (en)	2003-05-01
US20050054845A1 (en)	2005-03-10
EP1448223B1 (de)	2008-01-02
UA81613C2 (ru)	2008-01-25
EP1448223A2 (de)	2004-08-25
CY1107371T1 (el)	2012-12-19

Legal Events

Date	Code	Title	Description
2010-01-29	DISC	Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
NZ319377A (en)	2000-01-28	polypeptides comprising a portion of a soluble M tuberculosis antigen
WO2006041866A3 (en)	2006-09-08	Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
WO2007067681A3 (en)	2008-01-03	Immunostimulatory compositions and methods
EP1536009A4 (de)	2006-06-07	Hla-a24-restringiertes krebsantigenpeptid
IL202978A0 (en)	2011-08-01	West nile virus vaccine
AU2003256912A8 (en)	2004-03-03	Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2005028496A3 (en)	2005-10-06	Vaccine for treatment and prevention of herpes simplex virus infection
WO2001096370A3 (en)	2003-01-03	Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
EP1581638A4 (de)	2005-12-28	P153- und p156-antigene zur immundiagnose von ehrlichiose in hunden und menschen und verwendungen davon
MXPA06013388A (es)	2007-06-19	Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
WO2003093298A3 (en)	2006-02-02	Immunogenic peptides
IL161603A0 (en)	2004-09-27	Thymosin augmentation of genetic immunization
WO2002040518A8 (fr)	2002-06-20	Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur ou adjuvant
WO2004058807A3 (en)	2004-09-30	Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
WO2004041853A3 (en)	2004-07-15	Hcv vaccine compositions comprising e1 and ns3 peptides
WO2005056051A3 (en)	2005-09-29	Hepatitis b vaccines and compositions
AU8349301A (en)	2002-01-30	Dna vaccines encoding hiv accessory proteins
AU2003208197A8 (en)	2003-09-16	Use of soluble fgl2 as an immunosuppressant
ATE476197T1 (de)	2010-08-15	Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
AU6761301A (en)	2001-12-17	Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002004497A3 (en)	2002-08-01	Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2005010035A3 (en)	2006-09-08	Alternate reading frame polypeptides derived from hepatitis c and methods of their use
SE9600436D0 (sv)	1996-02-06	Vaccine against hantavirus
WO2002030458A8 (en)	2002-07-18	Yersinia adhesion protein as vaccine adjuvant
EP1222928A3 (de)	2003-11-05	Pharmaceutische Zusammensetzungen zur Vorbeugung oder Behandlung von Krebs, insbesondere Melanome